Press Releases

May 5, 2026

Avery Klein

Press Releases

Cytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy

Cytokinetics announced that the pivotal Phase 3 ACACIA-HCM trial of aficamten met both of its primary endpoints, showing statistically significant improvements in symptoms and exercise capacity in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (HCM). The drug demonstrated consistent benefits across key secondary measures with…

CYTK

May 5, 2026

Caleb Monroe

Press Releases

Telesat reports results for the quarter ended March 31, 2026

Telesat announced its Q1 2026 financial results showing a 25% revenue decline to CAD 87 million largely due to broadcast contract non-renewals in the GEO segment, while investing heavily (CAD 171 million) in its LEO Telesat Lightspeed constellation development targeted for commercial service launch around Q1 2028. The company reported a net loss of…

TSAT

May 5, 2026

Caleb Monroe

Press Releases

Rumble Announces Receipt of all Regulatory Approvals for Business Combination with Northern Data

Rumble Inc. has received the final regulatory approval from the UAE Ministry of Economy for its proposed business combination with Northern Data AG. The transaction has seen significant shareholder participation, with 77% of Northern Data shares secured under tender or support agreements. The combined entity seeks to leverage Northern Data's high-p…

RUM

May 5, 2026

Derek Hwang

Press Releases

Surgery Partners, Inc. Announces First Quarter 2026 Results Reaffirms Full Year 2026 Guidance

Surgery Partners, Inc. announced its Q1 2026 financial results, showing a 4.5% year-over-year revenue increase to $810.9 million, driven by a 4.4% rise in same-facility revenues. Despite these gains, the company reported a net loss of $35.9 million for the quarter. Adjusted EBITDA was slightly lower at $102.3 million compared to the prior year. The…

SGRY

May 5, 2026

Jordan Park

Press Releases

BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE

BridgeBio Pharma announced that primary results from its Phase 3 CALIBRATE trial of encaleret for autosomal dominant hypocalcemia type 1 (ADH1) will be presented at the 2026 European Congress of Endocrinology. Additional presentations on genetic testing and disease monitoring related to hypoparathyroidism and ADH1 will also be shared, highlighting …

BBIO

May 5, 2026

Sofia Navarro

Press Releases

Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update

Compass Therapeutics reported positive first quarter 2026 financial results and highlighted significant progress in its oncology pipeline. The Phase 2/3 study of tovecimig (DLL4 x VEGF-A bispecific antibody) combined with paclitaxel showed statistically significant improvements in progression-free survival and overall response rate in biliary tract…

CMPX

May 5, 2026

Priya Menon

Press Releases

Kura Oncology to Report First Quarter 2026 Financial Results

Kura Oncology, a biopharmaceutical company specializing in precision cancer medicines, will report its first quarter 2026 financial results on May 12, 2026. The company will host a webcast and conference call to discuss the results and provide a corporate update. Kura is known for KOMZIFTI, an FDA-approved oral menin inhibitor for certain leukemia …

KURA

May 5, 2026

Ajmal Hussain

Press Releases

Intellia Therapeutics to Participate in Upcoming Investor Conferences

Intellia Therapeutics, a clinical-stage biopharmaceutical company focused on CRISPR gene editing, will participate in investor fireside chats at three major healthcare conferences in May and June 2026. The events will be webcast live, offering investors insights into the company's mission to develop potentially curative treatments targeting the roo…

NTLA

May 5, 2026

Marcus Reed

Press Releases

Exodus Movement, Inc. to Announce First Quarter 2026 Results on May 12, 2026

Exodus Movement, Inc., a self-custodial payments and cryptocurrency platform, announced it will release its financial results for the first quarter of 2026 on May 12, 2026, after market close. The company will host an earnings webcast that day and provide supplementary materials on its website. Founded in 2015 and headquartered in Omaha, Nebraska, …

EXOD

May 5, 2026

Ajmal Hussain

Press Releases

Cipher Digital Provides First Quarter 2026 Business Update

Cipher Digital reported significant progress in Q1 2026 with development milestones at its Barber Lake and Black Pearl data center campuses on schedule, signing a third AI data center lease with an investment-grade hyperscale tenant, and securing a $200 million revolving credit facility from leading global financial institutions to support ongoing …

CIFR

May 5, 2026

Caleb Monroe

Press Releases

ArcelorMittal announces results of its General Meetings

At its General Meetings held on 5 May 2026, ArcelorMittal shareholders approved key corporate actions including a US$0.60 per share dividend distribution, re-election of current directors along with a new director, approval of share cancellation following buybacks, and renewal of board authorization to increase share capital. These approvals suppor…

MT

May 5, 2026

Sofia Navarro

Press Releases

Sow Good Secures $20 Million Non-Convertible Private Placement Credit Facility to Fund Critical Minerals Strategy

Sow Good Inc. announced a $20 million non-convertible private placement credit facility with Sagol Advisors to fund its strategic acquisition of the Nachu Graphite Project in Tanzania. This funding supports Sow Good's transition into critical minerals and battery anode materials development, enhancing its position in the battery materials supply ch…

SOWG

May 5, 2026

Marcus Reed

Press Releases

HII Reports First Quarter 2026 Results

Huntington Ingalls Industries reported first quarter fiscal 2026 revenues of $3.1 billion, up 13.4% year-over-year, driven by growth across its shipbuilding and mission technology segments. Despite higher revenues, operating margins declined slightly, leading to net earnings and diluted EPS of $149 million and $3.79 respectively, unchanged from the…

HII

May 5, 2026

Maya Rios

Press Releases

Fiserv Reports First Quarter 2026 Results

Fiserv, Inc. reported first quarter 2026 GAAP revenue of $5.03 billion, down 2% year-over-year, with organic revenue down 4%. GAAP EPS declined 29%, and adjusted EPS fell 16%. The company confirmed 2026 organic revenue growth guidance of 1%-3% and adjusted EPS between $8.00 and $8.30. Operating margins declined notably compared to prior year period…

FISV

May 5, 2026

Priya Menon

Press Releases

Colliers Reports First Quarter Results

Colliers International Group Inc. announced robust first quarter 2026 financial results, with consolidated revenues rising 15% to $1.31 billion and adjusted EBITDA increasing by 8% to $124.8 million. Adjusted EPS grew 5% to $0.91, reflecting the company's diversified professional services platform's resilience amid an uneven operating environment. …

CIGI

May 5, 2026

Hana Yamamoto

Press Releases

Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

Repligen Corporation reported a robust first quarter 2026 with revenues of $194 million, up 15% year-over-year, and adjusted EPS growth of 23%. The company reiterated its full-year organic revenue growth guidance of 9%-13%, while increasing adjusted EPS guidance to $1.97-$2.05. Key strategic moves include launching a Transformation Office to enhanc…

RGEN

May 5, 2026

Leila Farooq

Press Releases

NeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026

NeurAxis, Inc., a medical technology company specializing in neuromodulation therapies, will release its first quarter 2026 financial results on May 12, 2026, prior to market open. The company will also host a conference call to discuss the results and business update. NeurAxis focuses on the commercialization of its proprietary PENFS technology, I…

NRXS

May 5, 2026

Avery Klein

Press Releases

Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026

Relmada Therapeutics announced presentations of two abstracts related to NDV-01, their sustained-release gemcitabine-docetaxel formulation for non-muscle invasive bladder cancer (NMIBC), at the American Urology Association 2026 event. Phase 2 data in high-risk NMIBC patients showing 9-12 month efficacy results will be presented, alongside a Phase 3…

RLMD

May 5, 2026

Ajmal Hussain

Press Releases

Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026

Arvinas, a biotechnology company specializing in targeted protein degradation therapies, announced it will release its first quarter 2026 financial results on May 12, 2026, accompanied by a corporate update webcast. The company continues advancing multiple clinical-stage investigational drugs, including FDA-approved VEPPANU developed with Pfizer fo…

ARVN

May 5, 2026

Hana Yamamoto

Press Releases

EVgo Inc. Reports First Quarter 2026 Results with Record First Quarter Revenues

EVgo Inc. announced strong first quarter 2026 financial results, achieving record revenues of $110 million, a 45% increase year-over-year. The company expanded its public fast charging stalls by 25% to 5,280 and grew network throughput by 10%, reinforcing its leadership in the U.S. EV charging market. Key strategic initiatives include scaling the n…

EVGO

May 5, 2026

Marcus Reed

Press Releases

Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights

Ocular Therapeutix announced its first quarter 2026 financial results along with significant clinical progress in its AXPAXLI program for wet age-related macular degeneration (wet AMD) and diabetic retinopathy. Key highlights include positive Phase 3 SOL-1 trial results demonstrating superiority over existing anti-VEGF treatment, initiation of the …

OCUL

May 5, 2026

Marcus Reed

Press Releases

Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)

Eupraxia Pharmaceuticals reported encouraging EREFS (Endoscopic Reference Score) data from the ongoing Phase 1b/2a RESOLVE trial evaluating EP-104GI for eosinophilic esophagitis (EoE). The data show that a higher number of esophageal wall injections (20 injections) resulted in significant improvement in inflammation and fibrosis scores, supporting …

EPRX

May 5, 2026

Priya Menon

Press Releases

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Initiation of Commercial Manufacturing for Preservative Free Ketamine

NRx Pharmaceuticals initiated commercial manufacturing of its preservative-free ketamine product utilizing an innovative blow-fill-seal process at a US-based facility. The product aims to address ongoing supply shortages in sterile intravenous ketamine, with production capacity supporting significant sales and scalability. This new formulation excl…

NRXP

May 5, 2026

Priya Menon

Press Releases

Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

Rhythm Pharmaceuticals announced first quarter 2026 financial results featuring $60.1 million in global net product revenue for IMCIVREE, a treatment for acquired hypothalamic obesity (HO) and rare genetic obesity disorders. The company reported a successful U.S. launch post FDA approval, received European Commission authorization expanding indicat…

RYTM

May 5, 2026

Marcus Reed

Press Releases

Fractyl Health to Report First Quarter 2026 Financial Results and Provide Business Updates on May 12, 2026, and Will Participate in an Upcoming Investor Conference

Fractyl Health, a clinical stage metabolic therapeutics company focused on innovative treatments for obesity and type 2 diabetes, will announce its Q1 2026 financial results and provide business updates on May 12, 2026. Additionally, CEO Dr. Harith Rajagopalan will present at the BofA Securities 2026 Health Care Conference on May 14, 2026.

GUTS